Regeneron Pharmaceuticals' Deferred Taxes rose 65.24% to $278.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $833.1 million, marking a year-over-year increase of 9.13%. This contributed to the annual value of $757.3 million for FY2024, which is 9.61% down from last year.
As of Q3 2025, Regeneron Pharmaceuticals' Deferred Taxes stood at $278.6 million, which was up 106.07% from $135.2 million recorded in Q2 2025.
Regeneron Pharmaceuticals' 5-year Deferred Taxes high stood at $286.3 million for Q4 2023, and its period low was -$41.7 million during Q2 2021.
For the 3-year period, Regeneron Pharmaceuticals' Deferred Taxes averaged around $195.3 million, with its median value being $190.4 million (2024).
Per our database at Business Quant, Regeneron Pharmaceuticals' Deferred Taxes crashed by 7,100.00% in 2021 and then soared by 2,327.72% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Deferred Taxes (Quarterly) stood at $205.9 million in 2021, then skyrocketed by 35.84% to $279.7 million in 2022, then grew by 2.36% to $286.3 million in 2023, then declined by 2.13% to $280.2 million in 2024, then surged by 65.24% to $278.6 million in 2025.
Its Deferred Taxes stands at $278.6 million for Q3 2025, versus $135.2 million for Q2 2025 and $139.1 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value